Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Remission of metastatic duodenal cancer after treatment with BRAF inhibitor].

Ugeskrift for laeger - 26 Jan 2026

Hansen Helene Benedikte, Bromann Julia Almer, Høgdall Dan, Schou Jakob Hagen Vasehus, Eefsen Rikke

Abstract excerpt

Encorafenib, cetuximab, and binimetinib are targeted therapies developed for metastatic colorectal cancer with a BRAF V600E mutation. This case report describes a patient with metastatic duodenal cancer with a BRAF V600E mutation who achieved durable complete remission following this treatment. The case highlights the potential use of BRAF V600E targeted therapy in BRAF V600E-mutated duodenal cancer and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Antineoplastic Agents
Share to Carbamates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Duodenal Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Remission Induction

Share to Sulfonamides

Source

Identifiers

PMID: 41614250
DOI: 10.61409/V08250650

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Remission of metastatic duodenal cancer after treatment with BRAF inhibitor].PMID 41614250Read ↗

[A Case of BRAF Mutant Cecal Cancer Treated with Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.Semantic proximity Read ↗

Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E-mutant rectal cancer with bowel obstruction.Semantic proximity Read ↗

[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].Semantic proximity Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

[Small bowel adenocarcinoma].Semantic proximity Read ↗

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab.Semantic proximity Read ↗

Small Bowel Adenocarcinoma.Semantic proximity Read ↗

Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy.Semantic proximity Read ↗

Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAFV600E Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series.Semantic proximity Read ↗

[Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib].Semantic proximity Read ↗

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.